


PHARMACEUTICAL 2019

GALECTIN THERAPEUTICS INC Rank 340 of 371





PHARMACEUTICAL 2019

GALECTIN THERAPEUTICS INC Rank 340 of 371

The relative strengths and weaknesses of GALECTIN THERAPEUTICS INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of GALECTIN THERAPEUTICS INC compared to the market average is the variable Other Expenses, increasing the Economic Capital Ratio by 74% points. The greatest weakness of GALECTIN THERAPEUTICS INC is the variable Net Income, reducing the Economic Capital Ratio by 523% points.

The company's Economic Capital Ratio, given in the ranking table, is -879%, being 548% points below the market average of -331%.

Input Variable	Value in 1000 USD
Assets, Current	8,832
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	0
Liabilities, Non-Current	0
Other Assets	174
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	2,108
Other Net Income	-298
Property and Equipment	0
Research and Development	6,471
Revenues	0
Selling, General and Administrative Expense	7,131

Output Variable	Value in 1000 USD
Assets	9,006
Liabilities	2,108
Expenses	13,602
Stockholders Equity	6,898
Net Income	-13,900
Comprehensive Net Income	-13,900
Economic Capital Ratio	-879%